Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB : NSDQ)
 
 • Company Description   
Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel.

Number of Employees: 20

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.05 Daily Weekly Monthly
20 Day Moving Average: 33,460 shares
Shares Outstanding: 11.40 (millions)
Market Capitalization: $34.78 (millions)
Beta: 1.17
52 Week High: $27.92
52 Week Low: $2.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.60% -2.68%
12 Week -22.00% -14.24%
Year To Date -55.80% -45.99%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
KIRYAT ATIDIM BUILDING 7
-
TEL AVIV,L3 6158002
ISR
ph: 972-77-331-0156
fax: -
arr@lifesciadvisors.com http://www.anchiano.com
 
 • General Corporate Information   
Officers
Dale Pfost - Chief Executive Officer and Chairman
Donald Marvin - Chief Financial Officer; Executive Vice President
Adi Mor - Director
Nissim Darvish - Director
Joel Maryles - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 16385C104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 11.40
Most Recent Split Date: 3.00 (0.06:1)
Beta: 1.17
Market Capitalization: $34.78 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.01 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.61
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -25.18
12/31/21 - -19.95
09/30/21 - -19.22
ROA
03/31/22 - -24.13
12/31/21 - -19.02
09/30/21 - -18.21
Current Ratio
03/31/22 - 16.87
12/31/21 - 23.66
09/30/21 - 40.39
Quick Ratio
03/31/22 - 16.87
12/31/21 - 23.66
09/30/21 - 40.39
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.02
12/31/21 - 5.39
09/30/21 - 5.75
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©